Lyell Immunopharma, Inc. (LYEL) earnings
Lyell Immunopharma, Inc. (LYEL) reported net income of -$274.45M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$342.99M. Figures as of 18 Nov 2026, 13:09 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Earnings (net income), fiscal 2025
- -$274.45M
- Highest on record
- -$129.38Mfiscal 2019
- Lowest on record
- -$342.99Mfiscal 2024
- Fiscal years on record
- 72019–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.
Lyell Immunopharma, Inc. earnings, in more detail
Across the 7 fiscal years on record (2019–2025), the highest was -$129.38M in fiscal 2019 and the lowest -$342.99M in fiscal 2024.
Earnings (net income) by fiscal year
Lyell Immunopharma, Inc. earnings, year by year
| Fiscal year | Earnings (net income) | Change | Year ended |
|---|---|---|---|
| 2025 | -$274.45M | — | |
| 2024 | -$342.99M | — | |
| 2023 | -$234.63M | — | |
| 2022 | -$183.12M | — | |
| 2021 | -$250.22M | — | |
| 2020 | -$204.47M | — | |
| 2019 | -$129.38M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.
How to read it
Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.
Lyell Immunopharma, Inc., figure by figure
- Lyell Immunopharma, Inc. market cap
- Lyell Immunopharma, Inc. revenue
- Lyell Immunopharma, Inc. earnings per share (EPS)
- Lyell Immunopharma, Inc. P/E ratio
- Lyell Immunopharma, Inc. P/S ratio
- Lyell Immunopharma, Inc. P/B ratio
- Lyell Immunopharma, Inc. free cash flow
- Lyell Immunopharma, Inc. operating margin
- Lyell Immunopharma, Inc. dividend
- Lyell Immunopharma, Inc. shares outstanding
- Lyell Immunopharma, Inc. total debt
- Lyell Immunopharma, Inc. cash on hand
- Lyell Immunopharma, Inc. total assets
- Lyell Immunopharma, Inc. return on equity (ROE)
- Lyell Immunopharma, Inc. return on invested capital (ROIC)
Lyell Immunopharma, Inc. (LYEL) overview: price, valuation and scorecard
Lyell Immunopharma, Inc. earnings: questions and answers
What is Lyell Immunopharma, Inc.'s net income?
Lyell Immunopharma, Inc. (LYEL) reported net income of -$274.45M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$342.99M.
What are the highest and lowest net income figures on record for Lyell Immunopharma, Inc.?
Across the 7 fiscal years on record (2019–2025), the highest was -$129.38M in fiscal 2019 and the lowest -$342.99M in fiscal 2024.
How is Lyell Immunopharma, Inc.'s net income calculated?
Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement. For Lyell Immunopharma, Inc. it is on record here for 7 fiscal years, 2019 to 2025.
Fiscal years are named for the calendar year they end in.
Learn: earnings
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Lyell Immunopharma, Inc. (LYEL) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/LYEL/earnings
Underlying data: the company's filings with the SEC and Yahoo Finance.